What is Wedbush's Forecast for NovoCure FY2026 Earnings?

NovoCure Limited (NASDAQ:NVCR - Free Report) - Research analysts at Wedbush raised their FY2026 earnings per share (EPS) estimates for shares of NovoCure in a research report issued on Monday, June 2nd. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will post earnings of ($1.56) per share for the year, up from their previous forecast of ($1.57). Wedbush currently has a "Neutral" rating and a $27.00 target price on the stock. The consensus estimate for NovoCure's current full-year earnings is ($1.30) per share.

A number of other analysts have also commented on the company. JPMorgan Chase & Co. cut their price target on NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Wall Street Zen lowered NovoCure from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Finally, Piper Sandler cut their target price on NovoCure from $42.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $32.83.

NovoCure Stock Up 3.3%

NVCR traded up $0.55 during trading on Thursday, hitting $17.00. The company had a trading volume of 2,844,994 shares, compared to its average volume of 1,166,731. The company has a market capitalization of $1.90 billion, a PE ratio of -12.14 and a beta of 0.73. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. NovoCure has a one year low of $14.17 and a one year high of $34.13. The firm's 50-day moving average price is $17.37 and its 200 day moving average price is $21.87.

NovoCure (NASDAQ:NVCR - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.16. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The firm had revenue of $154.99 million for the quarter, compared to analyst estimates of $147.57 million. During the same quarter in the previous year, the firm posted ($0.36) earnings per share. The business's revenue was up 11.9% on a year-over-year basis.

Hedge Funds Weigh In On NovoCure

Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in NovoCure during the fourth quarter worth about $272,000. Ameriprise Financial Inc. raised its stake in shares of NovoCure by 77.7% during the 4th quarter. Ameriprise Financial Inc. now owns 22,883 shares of the medical equipment provider's stock worth $682,000 after purchasing an additional 10,007 shares in the last quarter. LPL Financial LLC acquired a new stake in shares of NovoCure in the 4th quarter valued at approximately $830,000. Los Angeles Capital Management LLC boosted its holdings in shares of NovoCure by 362.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 70,601 shares of the medical equipment provider's stock valued at $2,104,000 after buying an additional 55,334 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of NovoCure in the fourth quarter valued at $899,000. Institutional investors own 84.61% of the company's stock.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.